AQR Capital Management
ACRS icon

AQR Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

AQR Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Sell
60,259
-12,149
-17% -$54.2K ﹤0.01% 3603
2026
Q1 		$272K Sell
72,408
-31,384
-30% -$106K ﹤0.01% 3456
2025
Q4 		$312K Buy
103,792
+68,840
+197% +$174K ﹤0.01% 3151
2025
Q3 		$66.4K Buy
+34,952
New +$60.9K ﹤0.01% 3404
2024
Q3 		– Sell
-386,177
Closed -$425K – 2754
2024
Q2 		$425K Sell
386,177
-226,028
-37% -$266K ﹤0.01% 2122
2024
Q1 		$759K Buy
+612,205
New +$730K ﹤0.01% 1800
2023
Q2 		– Sell
-19,968
Closed -$162K – 2179
2023
Q1 		$162K Buy
19,968
+5,632
+39% +$71.5K ﹤0.01% 2083
2022
Q4 		$226K Buy
14,336
+3,174
+28% +$51.1K ﹤0.01% 2051
2022
Q3 		$176K Buy
11,162
+410
+4% +$6.46K ﹤0.01% 2060
2022
Q2 		$150K Sell
10,752
-64
-0.6% -$897 ﹤0.01% 2035
2022
Q1 		$186K Sell
10,816
-9,119
-46% -$124K ﹤0.01% 2080
2021
Q4 		$290K Sell
19,935
-39,761
-67% -$602K ﹤0.01% 1987
2021
Q3 		$1.07M Buy
59,696
+29,433
+97% +$472K ﹤0.01% 1497
2021
Q2 		$531K Buy
+30,263
New +$687K ﹤0.01% 1880
2017
Q4 		– Sell
-10,625
Closed -$274K – 2217
2017
Q3 		$274K Sell
10,625
-200
-2% -$5.36K ﹤0.01% 2107
2017
Q2 		$294K Buy
+10,825
New +$294K ﹤0.01% 2045

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

AQR Capital Management's ACRS Position: Q2 2026 in Review

AQR Capital Management reduced its Aclaris Therapeutics (ACRS) stake by 17% in Q2 2026, selling an estimated $54.2K and leaving 60,259 shares worth $319K. The position accounts for ﹤0.01% of the portfolio, ranked #3603.

AQR Capital Management first reported a position in ACRS in Q2 2017 and has held it in 16 quarters since. The position peaked at $1.07M in Q3 2021. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • AQR Capital Management held 60,259 shares of Aclaris Therapeutics worth $319K as of Q2 2026.
  • AQR Capital Management sold 12,149 Aclaris Therapeutics shares in Q2 2026, an estimated $54.2K.
  • Aclaris Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3603 holding.
  • AQR Capital Management first reported a position in Aclaris Therapeutics in Q2 2017 and has held it in 16 quarters since.
  • AQR Capital Management's Aclaris Therapeutics position peaked at $1.07M in Q3 2021.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.